Organic Active Ingredients TRIZ Cases

Substituted pyridine compounds support stable parenteral delivery when unconscious TBI or stroke patients cannot receive oral medication.

CSF1R-resistant microglia survive inhibitor treatment while endogenous microglia are cleared, creating a selective path to CNS engraftment.

Formula (I) compounds inhibit KRas G12A, G12C, G12D, G12R, G12S, G12V, G13D, and Q61H to broaden activity across mutations.

This case examines Formula I compounds that activate GLP-1R to support oral treatment options for diabetes, obesity, and NASH.

Selective compounds target GSK3 and CK1 to improve kinase inhibition while minimizing off-target effects in disease treatment.

Epitope-presenting peptide complexes guide T-cell receptor engagement, enabling more specific T-cell activation or inhibition than broad costimulatory signaling.

Aluminum adjuvants can limit Th1 and cellular immunity; mineralized zinc risedronate particles broaden vaccine responses.

Rapid uridine clearance limits therapy for 5-FU-induced mucositis; an anhydropyrimidine inhibitor maintains higher levels and supports mucosal health.

Selected gene and protein inhibitors promote hepatocyte proliferation and liver regeneration while helping prevent or reverse fibrosis.

Multiple crystalline, hydrate, and solvate forms of a KRAS G12C inhibitor address solubility and stability limits in pharmaceutical formulation.

Low aqueous dissolution limits steviol glycoside sweeteners; enhancer compounds enable higher concentrations and improved sweetness intensity.

Specific pyridine substituents target PARP1 over PARP2, supporting DNA damage in HRD and BRCA1/2-mutant cancers with reduced toxicity.

Replacing local prostaglandins with daily tafoxiparin targets cervical ripening and labor onset without the associated hypercontractility risk.

NR2B-selective modulation and titrated maintenance dosing reduce seizure frequency and severity while minimizing psychotomimetic side effects.

Small molecules block pathogen group II intron RNA splicing, suppressing growth while minimizing toxicity to mammalian cells.

Small molecules stabilize mutant p53 and restore DNA binding, helping identify compounds that reactivate tumor suppression.

Polymorphs, salts, solvates, co-crystals, and amorphous forms are characterized to balance stability, purity, dissolution, and bioavailability.

Pyrophoric reagents and column chromatography complicate scale-up; mild reduction and recrystallization support high-purity chroman production.

Specific azaquinolone substituents target PARP1 selectively, helping reduce off-target toxicity while preserving strong inhibition.

RAF and MEK inhibitors can trigger ERK reactivation; azaindole derivatives directly inhibit ERK kinases to address treatment resistance.

Substituted compounds directly modulate muscarinic receptors to address partial treatment response and refractory disorder symptoms.

Non-selective antibody coupling creates heterogeneous payload mixtures; defined Diels-Alder attachment improves site consistency for therapeutic and imaging conjugates.

Fucoidan, tauroursodeoxycholic acid, and VEGF in mixture 4F improve stem-cell proliferation, mobility, survival, and angiogenic regeneration.

Combining an SAE inhibitor with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy aims to improve response in resistant solid tumors.

LNA gapmer antisense oligomers target PCSK9 mRNA while preserving inhibition efficacy and reducing kidney toxicity.

An aqueous moisture-barrier coating helps ribociclib tablets resist cracking while improving stability during high-drug-load formulation.

An anti-PD-L1 antibody and anlotinib combine to inhibit the PD-L1 pathway, restore T-cell activity, and reduce tumor growth.

Selective S1P1 modulation with oral ponesimod reduces relapses and slows progression without injection or infusion.

Engineered bacteria degrade oxalate in the gut, offering a compliance-independent approach to limited hyperoxaluria treatments.

An airless metered pump and detachable sponge-tip wand apply topical drugs without rubbing, reducing greasy contact and application burden.

Taxifolin inhibits CD36 at low concentrations to help prevent or treat hepatocarcinoma arising from NASH.

Modified apolipoprotein fragments bind macrophages to concentrate therapeutic agents at plaques or tumors while limiting systemic toxicity.

Compound 1 maintains enhanced URAT1 potency while reducing CYP2C9 metabolism and hepatotoxicity for gout and hyperuricemia.

Novel spirooxindole compounds block MDM2-p53 interaction while addressing poor metabolic stability and limited therapeutic durability.

RNA hydrolysis complicates cold storage; stabilizing compositions protect RNA above freezing without lyophilization.

Synthetic infant nutrition with human milk oligosaccharides supports gut maturation and barrier integrity while addressing necrotizing enterocolitis risk.

Extrusion-generated emulsion droplets avoid sonication heat while encapsulating heat-sensitive drugs and live microorganisms.

A propellant-free treprostinil liquid supports stable storage and small-particle nebulization in a soft mist inhaler for lung deposition.

Blood biomarker panels support non-invasive endometriosis assessment with improved sensitivity and specificity, reducing reliance on costly, risky laparoscopy.

Polymeric oxobutanol esters enable continuous 3-hydroxybutyrate release with improved physiological compatibility and lower toxicity.

Limited FXR targeting in metabolic and liver disease is addressed through varied agonist structures that tune receptor affinity and selectivity.

Nanoporous membranes control therapeutic-agent diffusion while anti-inflammatory agents limit implant-site degradation and improve plasma exposure.

Sequential donor-template delivery with an integration-defective lentiviral vector supports HDR while limiting DNA damage in hematopoietic stem cells.

Limited treatments for regulated cell death are addressed with indole compounds that inhibit necrosis and ferroptosis by reducing lipid peroxides and ROS.

LSD1 inhibition helps CAR-T cells retain memory phenotype, limit exhaustion, and sustain antitumor activity during cancer treatment.

Caspase inhibitors target pyroptosis in T cells to limit inflammatory responses and morbidity from positive-sense RNA virus infections.

SAT1 inhibitors alter T-cell polyamine metabolism, reducing suppressive populations and improving tumor response to immunotherapy.

The case develops KRAS compounds that target G12D activity while balancing oral delivery, mutant selectivity, potency, and pharmacokinetics.

TDMQ20 targets cancer-cell copper to trigger ROS, mitochondrial damage, and apoptosis while showing greater selectivity than 5-FU.

These heterocyclic compositions target multiple cancer pathways to support tumor shrinkage while limiting acquired resistance in melanoma and non-small cell lung cancer.

Triblock copolymer matrix sustains ivermectin levels for twenty one days, resolving frequent dosing complexity.

5,6-bisaryl-2-pyridine-carboxamide compounds antagonize Urotensin II receptors, addressing the lack of effective treatments for hypertension and heart failure.

Segmented FGF-2 mimics boost signaling activity to improve recovery from brain injuries without complex polypeptide delivery.

Chiral auxiliary stereocontrol during preliminary synthesis eliminates chiral HPLC purification, reducing material loss and equipment investment.

Apigenin and hesperidin compositions modulate COX-2, TRPV1, and CGRP concentrations to relieve joint inflammation without NSAID side effects.

Segmented polymeric struts provide radial support while eliminating restenosis risk without increasing device complexity or manufacturing difficulty.

Amide substituted indole compounds inhibit Toll-like receptor 7, 8, and 9 signaling to reduce inflammatory responses in autoimmune diseases.

An implantable device uses a biodegradable polymer to release anabolic agents, eliminating tissue injury from dressing removal.

Fused bicyclic compounds inhibit USP30 to restore mitochondrial health by promoting mitophagy in neurodegenerative disease contexts.

Modified RNAi oligonucleotides sustain ALDH2 inhibition to overcome disulfiram compliance issues.

Conjugating perillyl alcohol with chemotherapeutics overcomes intrinsic drug resistance in malignant gliomas, improving treatment efficacy.

Multi-component botanical formulation blocks prostaglandin transport across cell membranes, reducing blood pressure without synthetic NSAID side effects.

Solid dispersion of amorphous efinaconazole with HPMC or PVP prevents thermodynamic deformation from ambient humidity, extending storage period.

Aceclidine and brimonidine combination treats presbyopia by inducing pinhole pupil constriction while preventing ciliary spasm.

A combination kidney and liver dialysis system separates blood plasma to enable targeted toxin removal through multiple membrane processes.

Magnesium oxide hydrate prevents particle agglomeration to improve bioavailability and reduce gastrointestinal side effects.

Segmented coating isolates oxycodone from degrading acetaminophen while masking bitterness for stable, rapid oral delivery.

Aqueous dosage form uses potassium sorbate to facilitate rapid diffusion of amino group active agents through mucous membranes.

UTMD-mediated nuclear localization of GLP-1 stimulates myocardial regeneration and reverses established cardiomyopathy.

De-solvating dolutegravir sodium pentanol solvate yields stable Form-L9 and Form-L12 polymorphs with distinct X-ray diffraction patterns.

Oral lactoferrin binds heparin sulfate proteoglycans to block viral attachment, addressing the lack of effective prevention treatments for SARS-CoV-2.

A dietary supplement combines tianeptine, sakae naa, kava, CDP Choline, and Alpha GPC to deliver multiple biological effects.

Covalent nitric ester modification of saquinavir enhances antitumor activity while eliminating systemic toxicity.

Dual inhibition of ERK and JAK pathways reduces malignant cell proliferation and bone marrow fibrosis, addressing limited efficacy of single-target therapies.

Amorphous solid dispersion of pyrazole-amide compound uses HPMCAS polymer to maintain solubility despite fasting conditions.

Dihydroxy-substituted TRPV1 antagonists modulate receptor affinity to treat chronic pain while reducing adverse side effects.

A silica carrier with controlled pore volume and radius holds amorphous drugs to boost solubility.

A composite herbal formulation merges multiple botanical extracts and vitamins into a single dosage form for immune support.

Sodium alginate forms a protective gel barrier in the stomach to block acid reflux into the esophagus.

4-Aminopyrimidine compounds mobilize cancer cells from bone marrow into peripheral blood to improve chemotherapy accessibility.

N4-phenyl-quinazoline-4-amine derivatives inhibit type I receptor tyrosine kinases to treat hyperproliferative disorders.

Replacing phosphoester bonds with phosphonoalkyl linkages prevents enzymatic hydrolysis, extending duration of action for vaccine adjuvants.

Fermenting soybean hypocotyls with equol-producing microorganisms resolves allergenicity while increasing equol content for safe consumption.

Hydroalcoholic chlorhexidine composition uses disodium eosin to provide visible red coloring for surgical antisepsis.

Spray drying amide derivatives with water-soluble polymers creates solid dispersions that enhance oral absorption while maintaining chemical stability.

Di- and tri-heteroaryl derivatives bind misfolded proteins to prevent aggregation, addressing chronic accumulation in neurodegenerative diseases.

A biodegradable chitosan paste provides conformal sinus stenting via mucoadhesion.

Biodegradable poly(diol fumarate) microparticles deliver voriconazole locally, reducing fungal burden while avoiding systemic therapy limitations.

Dipyridamole inhibits nucleoside transporter ENT2, reducing autoantibody infiltration into brain tissue and mitigating autoimmune disease pathology.

Combining CHK1 and WEE1 inhibitors creates a synergistic effect that enhances anti-proliferative activity in cancer cells.

Bivalent Smac mimetics inhibit XIAP to overcome apoptosis resistance and improve chemotherapy efficacy.

Specific prebiotic fiber ratios shift microbial metabolism from producing anxiety-linked 4-EPS to beneficial short-chain fatty acids.

2',3'-Methylidene acetal prodrugs mask adenosine to boost oral bioavailability, reducing hypotension risks while maintaining analgesic efficacy.

Crystalline form K of rivaroxaban achieves high purity through optimized reaction conditions.

Molecular NanoMotors convert electrostatic energy into kinetic energy to drive macromolecules across biological membranes.

Targeted nutritional components reverse liver fibrosis by addressing altered metabolic pathways and reducing oxidative stress.

Viscosity enhancement retains medication in the target area, preventing diffusion outside the epidural space and reducing adverse effects.

Novel indole compounds modulate aryl hydrocarbon receptor activity to stimulate the immune system.

A beeswax-based lipid composition maintains release profile consistency under mechanical stress.

Pairing EGFR inhibitors with TNF antagonists blocks adaptive resistance signals in wild-type tumors.

Hydrophilic and hydrophobic polymer compounds bond to oligonucleotides to form nanoparticles that target specific cells via receptor-mediated endocytosis.

Combining small diffusible compounds with corticosteroids enhances utrophin expression to treat muscular dystrophy.

Blocking IL-6 signaling preserves pre-existing humoral immunity, reducing cytomegalovirus reactivation risk after bone marrow transplantation.

Hovenia dulcis extract activates the Wnt/beta-catenin signaling pathway to promote osteoblast activity and bone tissue growth.

Humanized antibodies targeting folate receptor 1 reduce mean tumor volume by delivering cytotoxic agents specifically to FOLR1-expressing cells.

Amorphous solid dispersions of nilotinib stabilize drug release to eliminate food-dependent dosing restrictions.

Benzodioxole derivatives inhibit acetylcholinesterase, extending therapeutic duration while reducing adverse effects.

Prodrug formulations restrict dopamine D2 antagonists to peripheral tissue, preventing central nervous system entry and cardiac side effects.

Combining TUDCA, CoQ10, and creatine reduces inflammatory cytokines while improving neuronal health to address side effects from high-dose monotherapies.

Segmented nasal deposition and dynamic gel transitions extend action duration while preventing unwanted testosterone blood level spikes.

Bicyclic heteroaryl compounds modulate gamma-secretase activity to shift amyloid-beta cleavage toward shorter isoforms, reducing neurotoxic plaque formation.

Quinolin-2(1H)-one compounds block late SV40 factor transcription to increase tubulin acetylation and overcome hepatocellular carcinoma resistance.

Indazole derivatives target CYP11B2 to lower aldosterone while sparing cortisol, avoiding steroid side effects.

RPA1 agent enhances DNA repair mechanisms to alleviate spinocerebellar ataxia symptoms by targeting ATXN1 suppression.

BPI proteins mitigate hematopoietic toxicity and bone marrow damage during systemic radiation therapy.

A dialysate composition using citric acid and citrate salts to stabilize ionized calcium concentrations in blood purification fluids.

Host-guest interactions enable supramolecular cell-based carriers to achieve high biocompatibility and physiological barrier permeability.

Peptoid molecules bind phosphatidylserine on cancer cell membranes, bypassing protein biomarker heterogeneity.

Agmatine salt formulations delay protonation to enhance cellular uptake, overcoming the low bioavailability of agmatine sulfate.

Silica nanoparticles with PEG coatings and folic acid ligands overcome poor tumor penetration and limited drug loading of antibody platforms.

Standardized oat-derived beta-glucan converts immunosuppressive melanoma environments into immunogenic states via targeted macrophage activation.

Thermal processing of mRNA-lipid nanoparticles during solution exchange boosts encapsulation efficiency and therapeutic consistency.

A therapeutic agent combining citrulline and glutathione protects brain neuronal cells through synergistic antioxidant and vasodilatory mechanisms.

A PIC-Nal nanoliposome formulation conjugates BPD photosensitizers to cetuximab for targeted delivery.

Taxifolin glucoside and N-acetyl tyrosine reduce grey hair density by stimulating melanin synthesis while protecting melanocytes from oxidative stress.

Combines thiazolidinediones with corticosteroids to address fibrosis in eosinophilic esophagitis.

Cacao polyphenol composition increases serum brain-derived neurotrophic factor levels through targeted molecular weight fractionation.

Merges low-dose mitragyna and cannabis extracts to treat skin disorders while reducing addiction and liver damage risks.

Reversible self-assembly of iron ions with natural ligands enables sustained drug delivery over 90 days, reducing toxicity while improving targeted efficacy.

Mixed alcohol and alkane solvents precipitate an allisartan isoproxil polymorph that eliminates electrostatic dust generation during pharmaceutical processing.

A dsRNA agent inhibits ANGPTL3 expression to lower lipid levels.

Piperazine and piperidine compounds potentiate mGluR5 receptor function to treat neurological disorders linked to glutamate dysfunction.

Triblock copolymer stabilizes lipid nanoparticles against aggregation during nebulization, maintaining transfection efficiency.

A composite structural material blends hydrophobic and hydrophilic components to enable controlled pharmaceutical release.

Specific weight ratios of myo-inositol to D-chiro-inositol resolve insufficient insulin reduction by single agents, improving ovarian function.

Specific heterocyclic structures block pantetheine hydrolysis to reduce inflammation and oxidative stress in disease treatment.

Aryl compounds bind cereblon to degrade IKZF2, reducing systemic toxicity while enhancing anti-tumor immune responses.

A multilayer solid pharmaceutical dosage form uses permeable coating layers to control drug delivery rates.

Film combines hydroxypropyl cellulose with vinylpyrrolidone copolymer and titanium dioxide to achieve rapid disintegration without surfactants or polyalcohols.

Pyrimidine compound 1 solid forms target T790M mutations while sparing wild-type EGFR to reduce dose-limiting toxicities.

Fully humanized anti-PF4 antibodies mitigate heparin-induced thrombocytopenia by blocking platelet activation and aggregation.